AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study.

AstraZeneca Updates Real-World Study on Bleeding Treatment Ondexxya

Study Overview: This completed study, titled “Retrospective Real World Evidence Study to Describe Characteristics and Outcomes in Dutch Patients Admitted to the Hospital With a Factor Xa Inhibitor-associated Bleeding Treated With Andexanet Alfa,” looks at how AstraZeneca’s Ondexxya (andexanet alfa) is used in daily hospital practice in the Netherlands. It reviews patient profiles and outcomes for people admitted with serious bleeding linked to blood thinners called factor Xa inhibitors. The findings help doctors understand who receives Ondexxya and what happens after treatment, which also matters for long-term uptake and guideline support.

Intervention/Treatment: The study focuses on andexanet alfa, marketed as Ondexxya, a drug designed to reverse the effects of factor Xa inhibitor blood thinners in patients with severe bleeding. It is used as an emergency treatment to quickly stop or reduce life-threatening bleeding by neutralizing the action of these anticoagulants.

Study Design: This is an observational, retrospective cohort study. Researchers did not assign treatments but instead analyzed existing hospital records from about 10 Dutch hospitals. All included patients had already been given Ondexxya as part of normal care. The main goal was to describe real-world use and outcomes, including a closer look at those who later developed blood clots (thrombotic events). There was no randomization, no blinding, and no active comparison arm, which keeps the design simple but also means results show associations rather than cause and effect.

Study Timeline: AstraZeneca first submitted the study in April 2023, signaling early interest in structured real-world data around Ondexxya. The study has now been marked as completed, and an update was submitted on 4 February 2026, indicating new or refined analyses are available, especially around safety events. While formal results are not yet posted as a separate results entry, this recent update suggests the dataset is mature and will likely feed into ongoing discussions with clinicians and payers about how, and in whom, Ondexxya should be used.

Market Implications: For investors, the key data point disclosed is that 14 out of 218 patients (6.4%) experienced a blood clot within 30 days after Ondexxya treatment. This safety signal is not new conceptually—thrombosis risk is an expected concern with reversal agents—but real-world European data help refine the risk–benefit picture. If the in-depth analysis of these 14 cases shows that most events occurred in very high-risk patients, the study could support confidence in Ondexxya’s profile and help sustain or expand its use in line with Dutch national guidelines, where it competes with prothrombin complex concentrate (PCC). Stronger real-world backing may aid AstraZeneca in payer negotiations and hospital formulary decisions across Europe, which would modestly support long-term revenue from this specialized product. Conversely, if follow-up publications highlight higher-than-expected clot risks without clear clinical benefit in some groups, that could limit growth and strengthen the case for cheaper alternatives like PCC or rival reversal agents from competitors in the anticoagulation space. For AZN shares, any impact is likely to be incremental rather than transformational given Ondexxya’s niche role within AstraZeneca’s broader portfolio, but the update remains relevant for sentiment around the company’s ability to extract value from specialized hospital-focused therapies.

This study has been completed and recently updated, with further details and future analyses available on the ClinicalTrials.gov portal under identifier NCT05898412.

To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.